Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(7 sites)
China
Anyang Cancer Hospital, Anyang Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing Hunan Cancer Hospital, Changsha Fujian Cancer Hospital, Fuzhou Affiliated Obstetrics and Gynecology Hospital of Zhejiang University, Hangzhou Tianjin Cancer Hospital, Tianjin Henan Cancer Hospital, Zhengzhou